Indication-Based Pricing Hurdle A Block For Roche's Ocrevus In UK
The UK's National Institute for Health and Care Excellence rejected Roche's ocrelizumab for provision to adults with primary progressive multiple sclerosis due to cost grounds and efficacy uncertainties - but observers expect a compromise to be eventually struck.
You may also be interested in...
The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.
The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.